RE: Other investments8 Apr 2022 13:55
Hi Paul,
I agree with you about the lack of news on all the rest of BRH's investments, but as far as COVID testing is concerned I think they've been totally clear:
The RNS dated 25th of February – Operational Update (I thought) was quite clear and final:
First Paragraph
“The UK Government's decision to rapidly wind down the testing and isolation requirements for UK citizens and travellers to the UK has abruptly changed the nature of the COVID-19 test market which has led to a slowing of discussions with the remaining potential acquirers of Paraytec Limited and its COVID-19 test. It now appears unlikely that Braveheart will be able to conclude a sale with one of the remaining engaged parties at an acceptable price in the foreseeable future.”
I read this as – sorry – there will be no COVID only test sale.
Second Paragraph
“Braveheart's board believes that after the completion of the prospective clinical study, scheduled to be concluded by the end of June 2022 and provide clinical proof of concept of the CX300 technology platform, it would be in the best interests of shareholders that Paraytec focus on the development of the sepsis and bladder cancer applications for its technology.”
I read this as – sorry, the technology still has more tests to complete and they will conclude in June. After that we’ll concentrate on Sepsis and Bladder cancer applications of the technology.
I would love some clarity on the rest of the investments, but the COVID evangelists are peeing into the wind.